Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H7ClO6P2S.2Na |
Molecular Weight | 362.572 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OP([O-])(=O)C(SC1=CC=C(Cl)C=C1)P(O)([O-])=O
InChI
InChIKey=SKUHWSDHMJMHIW-UHFFFAOYSA-L
InChI=1S/C7H9ClO6P2S.2Na/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2
Molecular Formula | C7H7ClO6P2S |
Molecular Weight | 316.592 |
Charge | -2 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tiludronic acid is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates. Tiludronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and clodronate. Tiludronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the tiludronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Tiludronic acid is marketed under the tradename Skelid. In vitro studies indicate that tiludronate disodium acts primarily on bone through a
mechanism that involves inhibition of osteoclastic activity with a probable reduction in the
enzymatic and transport processes that lead to resorption of the mineralized matrix.
Bone resorption occurs following recruitment, activation, and polarization of osteoclasts.
Tiludronate disodium appears to inhibit osteoclasts through at least two mechanisms: disruption
of the cytoskeletal ring structure, possibly by inhibition of protein-tyrosine-phosphatase, thus
leading to detachment of osteoclasts from the bone surface and the inhibition of the osteoclastic proton pump. SKELID is indicated for treatment of Paget's disease of bone (osteitis deformans).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366048 |
|||
Target ID: CHEMBL612548 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SKELID Approved UseSKELID is indicated for treatment of Paget's disease of bone (osteitis deformans). Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
25 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
46.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
80 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
65.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8911885 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TILUDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 1 times / day steady, oral Studied dose Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: |
healthy, 18 - 45 years n = 10 Health Status: healthy Age Group: 18 - 45 years Sex: M Population Size: 10 Sources: |
|
1200 mg 1 times / day steady, oral Higher than recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 57 - 87 years n = 6 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 57 - 87 years Sex: M+F Population Size: 6 Sources: |
Other AEs: Gastrointestinal disturbance... Other AEs: Gastrointestinal disturbance (3 patients) Sources: |
600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
DLT: Gastrointestinal symptom NOS... Other AEs: Nausea, Diarrhoea... Dose limiting toxicities: Gastrointestinal symptom NOS (75%) Other AEs:Nausea (7 patients) Sources: Diarrhoea (7 patients) Arthralgia (2 patients) Dyspepsia (5 patients) Skeletal pain (3 patients) Vomiting (6 patients) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 72 years n = 29 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 72 years Sex: M+F Population Size: 29 Sources: |
DLT: Gastrointestinal symptom NOS... Dose limiting toxicities: Gastrointestinal symptom NOS (31%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gastrointestinal disturbance | 3 patients | 1200 mg 1 times / day steady, oral Higher than recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 57 - 87 years n = 6 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 57 - 87 years Sex: M+F Population Size: 6 Sources: |
Arthralgia | 2 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Skeletal pain | 3 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Dyspepsia | 5 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Vomiting | 6 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Diarrhoea | 7 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Nausea | 7 patients | 600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Gastrointestinal symptom NOS | 75% DLT, Disc. AE |
600 mg 1 times / day steady, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, 68 years n = 28 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 68 years Sex: M+F Population Size: 28 Sources: |
Gastrointestinal symptom NOS | 31% DLT, Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 72 years n = 29 Health Status: unhealthy Condition: Paget's disease of bone Age Group: 72 years Sex: M+F Population Size: 29 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. | 1988 |
|
Intermittent cyclic tiludronate in the treatment of osteoporosis. | 2001 |
|
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. | 2001 Apr |
|
Treatment of osteoporosis with bisphosphonates. | 2001 Feb |
|
Drugs in development: bisphosphonates and metalloproteinase inhibitors. | 2003 |
|
[Possible mechanism of the specific action of bisphosphonates on osteoclasts]. | 2003 Feb |
|
[Paget's disease and its therapeutic management]. | 2005 Apr 23 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. | 2005 May 31 |
|
Management of age-related osteoporosis and prevention of associated fractures. | 2006 Sep |
|
Use of zoledronic acid in the treatment of Paget's disease. | 2007 Oct |
|
Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods. | 2008 Nov 4 |
|
Paget disease of bone: therapeutic options. | 2008 Oct |
|
Once-yearly zoledronic acid in hip fracture prevention. | 2009 |
|
Paget's disease 2: exploring diagnosis, management and support strategies. | 2009 Feb 24-Mar 2 |
|
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. | 2013 Nov 1 |
Sample Use Guides
A single 400-mg daily oral dose of SKELID (Tiludronic acid), taken with 6 to 8 ounces of plain water
only, should be administered for a period of 3 months. Beverages other than plain water
(including mineral water), food (see below), and some medications. Patients should not lie down for at least 30 minutes after taking this medication. SKELID should not be taken within 2 hours of food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8889850
The ability of tiludronate to inhibit proton transport was 5-fold higher in kidney-derived chicken vesicles (IC50 = 1.1 mM) and 10,000-fold higher in vesicles derived from chicken osteoclasts (IC50 = 466 nM). Tiludronate also potently inhibited proton transport in yeast microsomal preparations (IC50 = 3.5 uM) and inhibited the activity of purified yeast V-ATPase.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:11:18 GMT 2023
by
admin
on
Sat Dec 16 05:11:18 GMT 2023
|
Record UNII |
BH6M93CIA0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67439
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
||
|
NCI_THESAURUS |
C443
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB04873MIG
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
100000128701
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
m10868
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1350
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
C61973
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
SUB36102
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
GG-14
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
60936
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
DTXSID1048621
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
DBSALT000411
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
83153
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
BH6M93CIA0
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY | |||
|
149845-07-8
Created by
admin on Sat Dec 16 05:11:18 GMT 2023 , Edited by admin on Sat Dec 16 05:11:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |